Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU

By: PRLog

MIYUN, China - April 17, 2025 - PRLog -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

  • Company name: Beijing Beilu pharmaceutical Co., Ltd.
  • Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
  • Registration number: RVG 132878
  • Drug name: Iohexol injection 350mg(I)/ml
  • Issuing authority: Netherlands Medicines Evaluation Board (MEB)
The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com

Contact
Beijing Beilu Pharmaceutical Co., Ltd. 
***@beilupharma.com

Photos: (Click photo to enlarge)

Beijing Beilu Pharmaceutical Co., Ltd. Logo Iohexol Injection Of Beilu Pharma Receives MA


Source: Beijing Beilu Pharmaceutical Co., Ltd. 

Read Full Story - Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU | More news from this source

Press release distribution by PRLog
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.